FOXK2 and cancer: Collectively, these results indicated that FOXK2 K223 deacetylation reduced cancer cell chemosensitivity to cisplatin by inhibiting cleaved‐PARP and cleaved‐caspase 3 expression and suggested that the FOXK2 acetylation status may be a prognostic biomarker in cancer chemotherapy.